Presentation Beckman Coulter with Notes (from

New Post Public Reply Private Reply Replies (1) Message Board
Sunny3999
2,475
Presentation Beckman Coulter with Notes (from Yahoo-Board):

Dr. Bruce Patterson thanks Beckman Coulter for the invitation.
20200522172851-img-5932.jpg
He wants to talk about Rantes/CCL5.
These are levels we've never seen before in Covid patients.
How do these immune cells get to sites of inflammation?
Rantes is an "immune magnet."
20200522172907-img-5933.jpg
We have looked at a set of very critical patients at Albert Einstein.
You see a very complex disease.
Rantes seems to be acting as the quarterback to bring cells to where they are needed.
But it brings them to such an extent that you get sequestration in lungs, liver, etc. The cytokyne storm is triggered.
20200522172942-img-5934.jpg
Macrophages and NK cells and lymphocytes come in and bring in new cells.
See in mild to moderate patients but this immune disruption/chaos doesn't start for a while.
It is tipped from the expression of Rantes.
It is well described in slide - initial virologic phase/sometimes asymptomatic - then uncontrolled response which leads to immune chaos/immune suppression and more cytokines.
20200522173034-img-5935.png
We were always trying to find a way to control.
Leron blocks binding of CCL5/Rantes and controls all the effects of Rantes.
We also found the immune disruption.
20200522173117-img-5936.png
Severely decreased CV4-CV8 cells also present.
We've been luck that we have tools to measure all the manifestations of Covid.
[Brags on his hardware]
20200522173207-img-5937.png
One of the discrepancies in the world is that no one knows why these drugs are working.
We have developed a suite of diagnostics that show what is happening.- i.e. increasing cells, decreasing IL6, decreasing viral lode.
This is the panel we've been using: i.e. T-Cell exhaustion.
We see dramatic decreases in IL6 in patients across the country
We are able to do cytokine panels right on the cytoplex.
20200522173240-img-5939.png
We can do profiling all on the same machine with three different assays.
In Covid patients, Rantes is increased to 3x to 5x quickly and that's the trigger from a viral disease to an immune disease.
That is borne out.
Platelets go up and are activated.
You can see why there may be issues with Thrombosis and coagulation.
C-reactive protein is high and it is brought down significant in patients on Leron.
Liver enzymes come down on Leron.
Recurring theme. The body is on fire in Covid. When you put out that fire, the viral load goes down which is remarkable.
These are all the key parameters. A lot of people talk about targeting various items i.e. IL6.
The diff with CCL5 is that it is initiating this storm.
The beauty is that Leron blocks CCL5 and brings down IL6.
The amazing thing about Rantes is that it crashes at day 14.
In some of the very severe patients, it comes down at day 21.
It determines two things 1) when do you initiate and 2) when do you stop.
The most astonishing finding in study under peer review: we were first to find and quantify viral load using droplet ...ICR. It is perfect technology.
We did find it in every single patient.
20200522173308-img-5940.png
Plasma viral load came down in these patients on Leron even though it is an immune modulator.
It essentially restores the immune system.
And quiets the cytokine storm.
All viral loads went down to undetectable at day 14.
Some things are not in paper.
20200522173356-img-5941.png
We saw decreases in immune exhaustion and markers.
Patients with renal failure had higher exhaustion.
The data has already been submitted for Leron in HIV.
Initially, when we advanced the theory that Leron might be effective in Covid, there was criticism, but we found the Rantes issue.
What we are finding in Covid immunologically also impacts the research in cancer and HIV.
All needs far more invest.
But these are exciting mechanisms previously undescribed.
In summary Covid, is biphasic heterogenous in 4 stages.
Very different distinctions in these phases.
Rantes signals the transition from virologic to immunologic disease.
Some patients were on life support and came off life support and are now home and at rehab facilities.
20200522173422-img-5942.png
It is anectodal, but my response is anectdotes don't come off life support.
We know what we have to do to prove to the community at large, but with 25 years experience, you know when something is working.
The effect is dramatic in moderate and severe.
The double blind studies are underway.
To date, there has been a disconnect between mechanism and outcome.
We see that in several other agents.
20200522173447-img-5943.png
There are a number of hurdles for other drugs that can't be used.
By looking at immunology of covid, we've learned a lot about this drug.
It is exciting to see something work like this beyond simply blocking a cytokine receptor.

Now questions:
Any competitors that have drugs that do same?
A: there are, like ___, which make CCL5 inhibitors. But, Leron is very close to submitting its trials to the FDA and we have a body of data that aligns the mechanism of operation with outcome. If we can remove the specter of death and intubation, we can get back to normal.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Infosys Pushes AI Growth with Strong Deal Wins

Updated Category News Views 17

Riding the AI Wave Who knew Infosys was a lightning rod for AI momentum, eh? With a 29% quarterly surge in AI revenue, the firm's really putting AI strategy at center stage. Considering today's finicky markets, that's not just peanuts. CEO Salil Parekh's swagger is backed by real numbers, seeing AI revenue inch to 10.5% of total haul. This ain't just talk—Infosys is...

Continue Reading
PZZA Faces Class Action: Strategic Shake-up or Misstep?

Updated Category News Views 10

Papa John's: Doughy Deceit or Strategic Misfire? Once in a while, a corporation trips over its own ambitious production line, and Papa John’s (NASDAQ:PZZA) is the latest contestant to make headlines for all the wrong reasons. Investors in this pizza powerhouse are being called to the courtroom as a class action lawsuit unfolds, marking a turbulent stage in the...

Continue Reading
FDA Nod for Subcutaneous SKYRIZI in Crohn's Disease

Updated Category News Views 48

AbbVie's Injection Makes Waves in Crohn's Treatment Here's a bit of medicine shake-up for you. AbbVie just snagged FDA approval for its subcutaneous SKYRIZI—specifically designed for adults battling moderately to severely active Crohn's disease. This news isn't just a blip on the radar; it's significant for patients and the healthcare landscape. We're talking about new...

Continue Reading
Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 37

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading
SLM Faces Legal Scrutiny as Losses Mount Amid Pause

Updated Category News Views 36

SLM's Latest Troubles: Legal and Financial Impact Ah, student loans—not just a headache for borrowers but now for lenders too. SLM Corporation, that name we know all too well in the student debt circus, has hit a snag. They've paused most of their third-party recovery activities. Let's dig in: net charge-offs for SLM in the third quarter shot up to a hefty $90.4...

Continue Reading
Pathalys' Phase 3 Data Shows Promise for CKD Drug

Updated Category News Views 30

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

Continue Reading
Stephen A. Smith Calls for Corporate Support of HBCUs

Updated Category News Views 4

A Stand for Education at the White House Stephen A. Smith stirred the pot with his decision to attend a White House dinner, a move that had tongues wagging across the media landscape. But this time, it wasn't about the usual hustle and bustle of the sports world. Smith had his sights set on the big picture, specifically, the long-term financial stability of Historically...

Continue Reading
Violet PR's Big Wins Hint at Industry Strategies

Updated Category News Views 15

A Shining Night in Morristown Picture Violet PR's team on top of the world, right there in Morristown, getting the accolades every agency dreams of—five awards from PRSA-NJ. It's not just an ego trip, either. This is about setting a high bar in the world of strategic communications, and they're flaunting their ability to drive growth and innovation in the economic...

Continue Reading
BOB Raises $5.5M for AI Banking Platform Revolution

Updated Category News Views 24

Cracking the Code of Small Business Finance BOB, a Miami hotshot aiming to be more than just another fintech flash in the pan, has wrangled a sweet $5.5 million in seed capital. They're shaking hands with big names like Peter Thiel and the mastermind behind Plaid, Zak Perret, through Mischief Ventures. The plan? To build an AI-powered finance savior for small businesses...

Continue Reading
GeeLark's Tech Leap: Expanding Cloud Phone Functions

Updated Category News Views 3

GeeLark's New Frontier GeeLark is kicking up some dust in the tech space by tooling up its cloud phone workflows with an arsenal of new supports: API, CLI, and MCP. This isn't just some minor patch, folks. It's a bold move, and for those in the quicksand of digital operations, a game-changer. You know how much of a drag it is repeating the same setup steps over and over?...

Continue Reading

Top 5 Most Recently Viewed Articles

CoinW Showcases Its Innovations at Taipei Blockchain Week 2024

Updated Category News Views 261

CoinW's Impactful Presence at Taipei Blockchain Week 2024 At the forefront of innovation and security, CoinW, a globally recognized cryptocurrency exchange, recently showcased its vision for the future during Taipei Blockchain Week 2024 as a Gold Sponsor. The event, celebrated for fostering discussions on blockchain advancements, featured the launch of PropW, CoinW's...

Continue Reading
Bank of Åland Plc Seeks Trading Admission of New Covered Bonds

Updated Category News Views 170

Application for Trading Admission of Covered Bonds Bank of Åland Plc, also recognized as Ålandsbanken Abp, is taking an important step by applying for the admission of a new security to trading on Nasdaq Helsinki. This involves their recent issuance of covered bonds, which are highly regarded in the financial market. Details of the Covered Bonds Issue The primary...

Continue Reading
Simpson Manufacturing's Q3 Earnings Report Shows Challenges Ahead

Updated Category News Views 54

Simpson Manufacturing's Third Quarter Performance Simpson Manufacturing Co., Inc. (NYSE: SSD) recently announced its third-quarter earnings, and the results did not meet the expectations of analysts. This disappointing performance resulted in a 5% decline in shares during after-hours trading. The company's focus on producing wood construction products highlights the...

Continue Reading
Alvotech Faces Challenges in Biologics License Approval Process

Updated Category News Views 349

Overview of Biologics License Application Status Alvotech, a prominent biotech firm specializing in biosimilars, has recently updated the market regarding its application status for AVT05, a potential competitor to Simponi (golimumab). The company has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) highlighting certain...

Continue Reading
Replimune Group Faces Class Action Lawsuit Amid FDA Setback

Updated Category News Views 127

Replimune Group Faces Class Action Lawsuit Amid FDA Setback Pomerantz LLP has brought attention to a class action lawsuit involving Replimune Group, Inc. (NASDAQ: REPL). This legal action is relevant for investors who have experienced losses on their investments in the company. It's crucial for affected investors to be proactive and consider their options as they navigate...

Continue Reading